Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Axitinib
Drug ID BADD_D00193
Description Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).[L6676] Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative.[A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations.
Indications and Usage Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
Marketing Status Prescription
ATC Code L01EK01
DrugBank ID DB06626
KEGG ID D03218
MeSH ID D000077784
PubChem ID 6450551
TTD Drug ID D01ZRI
NDC Product Code 54893-0043; 68554-0088; 54893-0032; 65344-0033; 63539-044; 0069-0151; 0069-0145; 63539-026
Synonyms Axitinib | AG 013736 | AG013736 | AG-013736 | Inlyta
Chemical Information
Molecular Formula C22H18N4OS
CAS Registry Number 319460-85-0
SMILES CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood sodium decreased13.11.01.012--Not Available
Blood thyroid stimulating hormone increased13.10.03.0060.004263%
Blood triglycerides increased13.12.03.0010.000799%Not Available
Blood urea increased13.13.01.0060.002131%Not Available
Blood uric acid increased13.02.04.0010.000533%Not Available
Bone pain15.02.01.0010.002131%
Bradycardia02.03.02.002--Not Available
Brain stem infarction24.04.06.014; 17.08.01.0240.000533%Not Available
Bronchopulmonary aspergillosis22.07.08.001; 11.03.01.0020.000278%Not Available
Burning sensation08.01.09.029; 17.02.06.001--Not Available
C-reactive protein increased13.09.01.0070.002131%Not Available
Cachexia16.32.03.011; 14.03.02.001; 08.01.01.0090.000139%Not Available
Cardiac arrest02.03.04.001--
Cardiac failure02.05.01.0010.001529%
Cardiac failure acute02.05.01.0050.000533%Not Available
Cardiac failure congestive02.05.01.002--Not Available
Cardio-respiratory arrest22.02.06.007; 02.03.04.002--Not Available
Cardiomyopathy02.04.01.001--Not Available
Cardiovascular disorder24.03.02.009; 02.01.01.001--Not Available
Cataract06.06.01.001--
Cellulitis23.09.01.001; 11.02.01.001--Not Available
Cerebral haemorrhage24.07.04.001; 17.08.01.003--Not Available
Cerebral infarction24.04.06.002; 17.08.01.0040.004795%Not Available
Cerebral ischaemia24.04.06.003; 17.08.01.0050.000799%
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chest discomfort22.02.08.001; 08.01.08.019; 02.02.02.009--Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.011--Not Available
Chills15.05.03.016; 08.01.09.001--
Choking22.02.05.0010.000208%Not Available
Cholangitis09.02.01.0020.001598%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 19 Pages